NCT00276536View on ClinicalTrials.gov

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Breast CancerKidney CancerLymphomaMelanomaMultiple MyelomaSarcomaUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

recombinant interferon alpha-1b

interferon

DRUG

IFN

IFN daily

Trial Locations (1)

44195-5044

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

The Cleveland Clinic

OTHER

NCT00276536 - Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma | Biotech Hunter | Biotech Hunter